Hey readers! This week's issue is less about the lab bench and more about where you can actually go: a brand-new adult clinic taking appointments, a trial recruiting volunteers right now, and an app worth keeping on your phone for gluten-free travel. There's a fascinating wrinkle buried in the research too - one study suggests that simply being watched closely in a trial can heal your gut, no drug required. More on that below.

UC Health launches first adult celiac disease center in the region - UC Health opened what it describes as the region's first comprehensive center for adults with celiac disease, non-celiac gluten sensitivity, abnormal celiac testing, and enteropathies. - WLWT

This is the kind of concrete resource that's genuinely hard to find: a single place offering diagnosis, dietician access, family screening, mineral monitoring, and clinical trial access under one roof. The office is at UC Health's Montgomery Medical Office on Montgomery Road, and appointments can be booked at 513-475-7505. If you or a family member has been bouncing between generalists, having a dedicated adult specialty center matters.

One detail we love: the collaboration with Cincinnati Children's Celiac Disease Center is aimed at the notoriously rocky handoff from pediatric to adult care.

Coeliac treatment: drug trial recruiting Australians living with the condition - The Walter and Eliza Hall Institute of Medical Research is inviting volunteers into a phase two trial aimed at switching off the immune response that gluten triggers. - The Nightly

If you're in Australia, this is an open door rather than a distant headline. The institute is seeking people aged 18 to 75 from Western Australia, Queensland, New South Wales, and Victoria who follow a gluten-free diet but still get inflammatory symptoms from cross-contamination or accidental exposure. The study involves a shortened "gluten challenge" followed by injections of the drug.

For U.S. readers, the Celiac Disease Foundation is an equally practical place to plug in; it helped recruit participants for the Teva study covered below, and is a good ongoing source if you want to be considered for research.

Teva Pharmaceuticals Announces Positive Phase 2a Results for Investigational Celiac Disease Treatment - Teva reported that its investigational antibody TEV '408, designed to block interleukin-15, significantly reduced gluten-induced intestinal damage and inflammation in a placebo-controlled study of 50 adults. - Celiac Disease Foundation

Here's what actually happened: participants got a single dose of TEV '408 or placebo, then completed a six-week gluten challenge under medical supervision. By eight weeks, the treated group showed less intestinal damage and lower gastrointestinal symptom scores. The Celiac Disease Foundation helped recruit patients, and its CEO framed it carefully.

A few things worth keeping in perspective. Per allsci's writeup, the primary endpoint (villous height-to-crypt depth ratio) showed a treatment difference of 0.45 (p<0.05), and intraepithelial lymphocyte density rose by 27.60 in the placebo arm versus just 0.37 with the drug. Teva has FDA Fast Track designation for the celiac indication. And Reuters notes celiac disease affects more than 3 million people in the U.S., which is a big part of why this readout drew attention.

The reality check on timing: per Ctech, Teva doesn't expect TEV '408 to reach the market before 2034, and the company still faces phase 3, regulatory endpoint agreement, and payer questions, as Biotech Insider lays out. Encouraging news, but the gluten-free diet remains the only established treatment for now.

Structured monitoring improves intestinal mucosa histology in celiac patients - A meta-analysis of 168 patients already on a gluten-free diet found that placebo and control groups showed a significant rise in the Vh/Cd ratio (+0.25; 95% CI 0.11-0.39; p<0.001) under structured monitoring. - Digestive and Liver Disease

The authors attribute this to the Hawthorne effect: people whose diets are being tracked closely simply do better, likely because tighter oversight reduces hidden gluten contamination. The practical takeaway is that structured follow-up itself, the kind a dedicated center like UC Health's offers, may improve your gut healing regardless of any new drug. It's also a reminder to read placebo-controlled celiac trials carefully.

Gluten-Free Diet Doesn't Fully Restore Gut Microbiome - Researchers followed 36 newly diagnosed celiac patients against 36 matched healthy volunteers using MRI and stool sequencing, at baseline and again after 12 months on a gluten-free diet. - Biome Science

Both gut function and microbiome composition improved on the diet, but neither fully caught up to healthy controls.

Important caveat: no probiotic or supplement was tested here. The authors simply flag microbiome-targeted add-ons as a future research direction, not a recommendation.

On the microbiome front, ProBiotix Health published a small pilot of its LP LDL® strain plus plant sterols in adults with celiac disease and high cholesterol, reporting improvements in lipid markers and gut diversity over nine weeks. It's an early, industry-run pilot, so treat it as a signal to watch rather than a reason to change your regimen.

While the drug pipeline develops, the everyday challenge stays the same: finding food you can trust. One resource we keep recommending is Find Me Gluten Free, a site and app with user reviews for restaurants and travel spots that flag cross-contamination risks. We're not sponsored by them; it's simply handy when you're navigating an unfamiliar city and don't want to interrogate every menu yourself.

That's it for this week. Whether you're booking a new specialist, eyeing a trial, or just planning safe takeout, we hope you found a concrete next step in here. Take care of yourselves.

Made with ❤️ by Data Drift Press